Cargando…
NSC95397 is a Novel HIV Latency Reversing Agent
The latent viral reservoir represents one of the major barriers of curing HIV. Focus on the “kick and kill” approach, in which virus expression is reactivated then cells producing virus are selectively depleted, has led to the discovery of many latency reversing agents (LRAs) that can reactivate lat...
Autores principales: | Nichols Doyle, Randilea, Yang, Vivian, Damoiseaux, Robert, Fregoso, Oliver I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245985/ https://www.ncbi.nlm.nih.gov/pubmed/37293110 http://dx.doi.org/10.1101/2023.05.24.542213 |
Ejemplares similares
-
NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway
por: Dubey, Navneet Kumar, et al.
Publicado: (2018) -
HIV Vpr Modulates the Host DNA Damage Response at Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair
por: Li, Donna, et al.
Publicado: (2020) -
Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021) -
Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance
por: Quan, Xingping, et al.
Publicado: (2019) -
HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)